CLDI (Calidi Bio) Forward P/E Multiple
Calidi Biotherapeutics (CLDI) is developing a universal platform to combat various types of tumors, ensuring high business scalability. This innovative approach has earned the company an impeccable reputation and the trust of the professional community. The historical price-to-earnings ratio for the company on GURU.Markets demonstrates the effectiveness of using stem cells for stealth virus delivery, and the 0.00 metric determines this level.
Summary analytical data breakdowns for Calidi Bio (CLDI)
- current price and projected stock value:
- business market valuation indicators:
- book capitalization information:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Calidi Biotherapeutics|CLDI - Long-Term Liabilities to Capital|Short-Term Debt to Capital Calidi Biotherapeutics|CLDI - Company Total Debt|Debts to Book Capitalization Calidi Biotherapeutics Inc.|CLDI - Company Long-Term Debts|Company Short-Term Debt Calidi Biotherapeutics|Quick Ratio calidibio.com
- financial results and valuation multiples details:
CLDI - Net Financial Result|Projected Future Earnings Calidi Biotherapeutics|CLDI - Price to Earnings Multiple|Forward P/E Multiple Calidi Biotherapeutics|CLDI - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio Calidi Biotherapeutics Inc.|CLDI - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Calidi Biotherapeutics|CLDI - Earnings per share for the last twelve months|Quarterly EPS earnings growth calidibio.com|CLDI - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Calidi Biotherapeutics
Fundamental company analysis:Calidi Biotherapeutics, Inc.
Strong confidence within the oncology community regarding the Calidi Biotherapeutics (CLDI) platform is driving inflated expectations, which are directly reflected in the dynamics of the company's forward P/E ratio. This indicator compares current market value with projected earnings, allowing investors to timely detect stock overvaluation or margin compression due to rising costs by analyzing price volatility through the lens of this chart.
Analysis of competing companies
Projected Price to Earnings ONC (BeiGene)|HALO (Halozyme Therapeutics, Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple RVMD (RevMed)|AAPG - Projected Price to Earnings|CGON: Projected Price to Earnings|URGN - Forward P/E Multiple|Bicara Therapeutics (BCAX) - Future Price to Earnings|Personalis Inc - Future Price to Earnings Multiple|ERAS (Erasca Corp) - Forward P/E Multiple|Projected Price to Earnings Ratio Delcath Corp DCTH|Forward P/E Multiple YMAB|Projected Price to Earnings aurabiosciences.com AURA|Forward P/E Multiple CADL (Candel Therapeutics, Inc.)|Forward P/E Multiple Accuray Inc ARAY|SLS - Future Price to Earnings|ACTU: Future Price to Earnings|CTOR: Forward P/E Multiple|HURA - Market Cap to Projected Earnings|TARA (Protara Therapeutics, Inc.) - Forward P/E Multiple|Price to Future Earnings Ratio FATE (Fate Therapeutics Inc)|Forward P/E Multiple WHWK|Market Cap to Projected Earnings tscan.com|Champions Oncology, Inc. - Projected Price to Earnings|Future Price to Earnings Multiple XBIT|CEL-SCI Corp - Forward P/E Multiple|OSTX: Future Price to Earnings|RADX: Forward P/E Multiple|ARTV - Market Cap to Projected Earnings|Future Price to Earnings Adlai Nortye Ltd|Projected Price to Earnings Ratio verupharma.com VERU|Projected Price to Earnings TPST (Tempest Therapeutics, Inc.)|Market Cap to Future Earnings Ratio XLO|Forward P/E Multiple RENB (Renovaro)|Future Price to Earnings Multiple MURA|Kairos Pharma Inc - Forward P/E Multiple|Projected Price to Earnings Ratio OnKure Therapeutics Inc|w2.cytomed.sg (GDTC) - Future Price to Earnings|Curis - Future Price to Earnings Multiple|APLM (Apollomics Inc.) - Forward P/E Multiple|Forward P/E Multiple Tharimmune Corporation|Future Price to Earnings Advanced Biomed Inc (ADVB)|GNPX: Price to Expected Earnings Ratio|Forward P/E Multiple SBFM (Sunshine Biopharma, Inc.)|Xenetic Biosciences Inc. (XBIO) - Projected Price to Earnings Ratio|SLRX: Projected Price to Earnings|PPBT - Forward P/E Multiple|AONC (aoncology.com) - Projected Price to Earnings|BGNE: Market Cap to Future Earnings Ratio|CKPT (Checkpoint Therapeutics, Inc.) - Forward P/E Multiple|elevationoncology.com (ELEV) - Market Cap to Projected Earnings|Forward P/E Multiple ICAD|Projected Price to Earnings ikenaoncology.com IKNA|Future Price to Earnings Notable Labs, Ltd. NTBL|Market Cap to Projected Earnings Viracta Therapeutics Inc. (VIRX)|MorphoSys - Forward P/E Multiple|NAYA Biosciences Inc (NAYA) - Projected Price to Earnings|Ascentage Pharma Group Ltd (AAPGV) - Future Price to Earnings
